10.6084/M9.FIGSHARE.20392981
Borwin Bandelow
Borwin
Bandelow
Christer Allgulander
Christer
Allgulander
David S. Baldwin
David S.
Baldwin
Daniel Lucas da Conceição Costa
Daniel Lucas
da Conceição Costa
Damiaan Denys
Damiaan
Denys
Nesrin Dilbaz
Nesrin
Dilbaz
Katharina Domschke
Katharina
Domschke
Eric Hollander
Eric
Hollander
Siegfried Kasper
Siegfried
Kasper
Hans-Jürgen Möller
Hans-Jürgen
Möller
Elias Eriksson
Elias
Eriksson
Naomi A. Fineberg
Naomi A.
Fineberg
Josef Hättenschwiler
Josef
Hättenschwiler
Hisanobu Kaiya
Hisanobu
Kaiya
Tatiana Karavaeva
Tatiana
Karavaeva
Martin A. Katzman
Martin A.
Katzman
Yong-Ku Kim
Yong-Ku
Kim
Takeshi Inoue
Takeshi
Inoue
Leslie Lim
Leslie
Lim
Vasilios Masdrakis
Vasilios
Masdrakis
José M. Menchón
José M.
Menchón
Euripedes C. Miguel
Euripedes C.
Miguel
Antônio E. Nardi
Antônio E.
Nardi
Stefano Pallanti
Stefano
Pallanti
Giampaolo Perna
Giampaolo
Perna
Dan Rujescu
Dan
Rujescu
Vladan Starcevic
Vladan
Starcevic
Dan J. Stein
Dan J.
Stein
Shih-Jen Tsai
Shih-Jen
Tsai
Michael Van Ameringen
Michael
Van Ameringen
Anna Vasileva
Anna
Vasileva
Zhen Wang
Zhen
Wang
Joseph Zohar
Joseph
Zohar
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
<p>This is the third version of the guideline of the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive–Compulsive and Posttraumatic Stress Disorders which was published in 2002 and revised in 2008.</p> <p>A consensus panel of 34 international experts representing 22 countries developed recommendations based on efficacy and acceptability of the treatments. In this version, not only medications but also psychotherapies and other non-pharmacological interventions were evaluated, applying the same rigorous methods that are standard for the assessment of medication treatments.</p> <p>The present paper (Part II) contains recommendations based on published randomised controlled trials (RCTs) for the treatment of OCD (<i>n</i> = 291) and PTSD (<i>n</i> = 234) in children, adolescents, and adults. The accompanying paper (Part I) contains the recommendations for the treatment of anxiety disorders.</p> <p>For OCD, first-line treatments are selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioural therapy (CBT). Internet-CBT was also superior to active controls. Several second-line medications are available, including clomipramine. For treatment-resistant cases, several options are available, including augmentation of SSRI treatment with antipsychotics and other drugs.</p> <p>Other non-pharmacological treatments, including repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS) and others were also evaluated.</p> <p>For PTSD, SSRIs and the SNRI venlafaxine are first-line treatments. CBT is the psychotherapy modality with the best body of evidence. For treatment-unresponsive patients, augmentation of SSRI treatment with antipsychotics may be an option.</p> <p>OCD and PTSD can be effectively treated with CBT and medications.</p>
Medicine
Pharmacology
Biotechnology
Science Policy
Mental Health
Plant Biology
Taylor & Francis
2022
2022-07-28
2023-05-30
Journal contribution
1233259 Bytes
10.1080/15622975.2022.2086296
CC BY 4.0